Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
PolyProx Therapeutics, a UK-based cancer therapy spinout of University of Cambridge, has raised £1m ($1.2m) of seed capital from medical research charity LifeArc. The funding will go toward in vivo proof-of-concept trials to support PolyProx’s planned series A financing in 2021. University of Cambridge’s tech transfer office Cambridge Enterprise and affiliated patient capital fund Cambridge Innovation Capital co-led a $4.4m seed round for PolyProx in May 2019 that also featured RT Capital. The spinout is working on a class…
